May 18, 2018 — Three year results of a study found injection of botulinum toxin into epicardial fat pads in patients ...
Here is an aggregation of all the news and late-breaking studies presented at the 2018 Heart Rhythm Society (HRS) ...
May 16, 2018 – The first results of the randomized, multicenter, long-term, international CABANA clinical trial were ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
May 10, 2018 – A new study is the first to test the clinical effectiveness of incremental peri-operative antibiotics as ...
Medical device manufacturer CardioFocus Inc. announced a successful live case featuring its HeartLight X3 System during the annual Prague Workshop on Catheter Ablation, April 21-24 in Prague, Czech Republic.
A new study published in JAMA Cardiology used the Zio continuous cardiac monitoring system by iRhythm to provide a comprehensive picture of the burden of atrial fibrillation (AF) in patients. Utilizing this data in combination with electronic health record data, the researchers concluded that an increase in AF burden is independently associated with a higher risk of ischemic stroke and arterial thromboembolism in patients who are not taking anticoagulant medication.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
May 16, 2018 — The Heart Rhythm Society (HRS) released communication recommendations to assist healthcare professionals ...
May 16, 2018 — A new study is the first to validate the accuracy of wrist-worn wearable devices in measuring induced ...
Itamar Medical Ltd. announced the launch of SleePath, the first integrated e-health sleep apnea care pathway monitoring system to monitor atrial fibrillation (AF) patients’ sleep apnea management status and compliance with continuous positive airway pressure (CPAP) devices on demand.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
May 16, 2018 — A new study shows that women exposed to particular matter (PM) and lower temperatures for even a short ...
“Disruptive innovation” is all the buzz. Repealing the Affordable Care Act (ACA) is so last year. Well, disrupt this ...
As a cardiologist practicing at the Orange County Heart Institute and St. Joseph Hospital in Orange, my mission is to ...
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Israel-based V-Wave Ltd. recently closed a $70 million Series C financing for its proprietary, minimally invasive implanted interatrial shunt device for treating patients with severe symptomatic heart failure (HF). The financing round was led by Deerfield Management, along with participation from new investors – healthcare funds Endeavour Vision, Quark Venture and Aperture Venture Partners. All of V-Wave's existing major investors are also participating in this round, including strategic investors Johnson & Johnson Innovation (JJDC Inc.) and Edwards Lifesciences, along with BRM Group, Pontifax, Pura Vida Investments, TriVentures, BioStar Ventures and Israel Secondary Fund.
Boston Scientific announced results from an analysis of the LATITUDE database evaluating the successful reduction of inappropriate shocks using the Smart Pass sensing filter with the Emblem Subcutaneous Implantable Defibrillator (S-ICD) System. The real-world data were presented during a late-breaking clinical trial at Heart Rhythm 2018, the Heart Rhythm Society's 39th Annual Scientific Sessions, May 9-12 in Boston. The results demonstrated that when the sensing filter was in use, the rate of inappropriate shocks was reduced to 4.3 percent at one year.
May 15, 2018 — A new study is the first to report a relationship between post-traumatic stress disorder (PTSD) and new ...